• News
  • SAN DIEGO
  • Finance

Optimer board to review strategic alternatives

Shares of Optimer Pharmaceuticals Inc. (Nasdaq: OPTR) jumped Wednesday on the possibility of a sale of the drug developer.

The company, which has an office in San Diego, said its board has started reviewing "a full range of strategic alternatives," to maximize shareholder value, and it named former Pfizer leader Hank McKinnell CEO for the duration of the review. McKinnell has served as Optimer chairman since April and had served as chairman and CEO of Pfizer, the world's largest drugmaker, from 2001 to 2006.

The company declined to elaborate on its review, aside from saying there are no guarantees any action will come from it.

Shares of Optimer climbed nearly 15 percent, or $1.59, to $12.31 in Wednesday morning trading. The stock had already climbed more than 18 percent in 2013 as of Tuesday's closing price of $10.72.

McKinnell replaces Pedro Lichtinger, who has served as CEO since May 2010. Optimer also said Kurt Hartman agreed to step down as general counsel and chief compliance officer. He'll be replaced by Meredith Schaum.

The company said independent directors told the board that management changes were appropriate after they reviewed compliance, record keeping and conflict of interest issues.

Last April, Optimer ousted former chairman Michael Chang and Chief Financial Officer John Prunty due to compliance issues tied to Chang's involvement with one of the company's subsidiaries.

Optimer said Wednesday the review by independent directors included "issues arising from the conduct of Optimer personnel who were the subject of the changes in management and leadership" announced in April.

Optimer will report fourth-quarter results Thursday. It said it recorded earnings totaling 2 cents per share in the final quarter of 2012.

The company said in early January that it also recorded $21.3 million in sales from its only marketed product, the antibacterial treatment Dificid.

RELATED ARTICLES:

Volcano shares slide to 3-year low on weak outlook

Illumina completes acquisition of Verinata Health

Encore Capital falls after court scuttles 'robo-signing' accord

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.